(Total Views: 576)
Posted On: 09/24/2024 9:21:00 AM
Post# of 154140
Madrigal only days 2 decide is my bet ($$ or not) ----
Leronlimab monotherapy (700 mg) appears to have better anti-fibrotic activity compared to Resmetirom (p=0.057).
we are very encouraged about the potential for leronlimab to support therapeutics meant to address MASH and specifically fibrosis and related complications in the liver.”
Notice the 3 bullet points are highlighted in blue?
Yep, they're excited alright... : ))))
Leronlimab monotherapy (700 mg) appears to have better anti-fibrotic activity compared to Resmetirom (p=0.057).
we are very encouraged about the potential for leronlimab to support therapeutics meant to address MASH and specifically fibrosis and related complications in the liver.”
Notice the 3 bullet points are highlighted in blue?
Yep, they're excited alright... : ))))
(1)
(0)
